Oral Ibrexafungerp Effective in Vulvovaginal Candidiasis Trial
Scynexis announced positive topline results from the phase 3 VANISH 303 trial of ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC) in women.
Scynexis announced positive topline results from the phase 3 VANISH 303 trial of ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC) in women.
Nearly one-third of patients with cystic fibrosis-related hospitalizations have aspergillosis, which is associated with worse outcomes.
The Food and Drug Administration (FDA) has granted Orphan Drug designation to MAT2203 (Matinas BioPharma) for the treatment of cryptococcosis.
The Food and Drug Administration (FDA) has granted Fast Track designations to both the oral and intravenous formulations of fosmanogepix (APX001; Amplyx Pharmaceuticals) for 7 antifungal indications, including treatment of: invasive candidiasis, invasive aspergillosis, scedosporiosis, fusariosis, mucormycosis, cryptococcosis and coccidioidomycosis. Fosmanogepix is a broad spectrum antifungal with a novel mechanism of action that has demonstrated…
Guideline addresses lab testing for diagnosis of fungal infections in pulmonary medicine, critical care
A total of 26 RCTs with 8136 patients were included in this network meta analysis.
Candida auris can survive on surfaces after routine cleaning and is often drug-resistant
This slideshow reviews drug information for Tolsura. This slideshow reviews drug information for Tolsura.
The Food and Drug Administration (FDA) has granted Orphan Drug designation to APX001 (Amplyx Pharmaceuticals) for the treatment of cryptococcosis.
Tolsura, which contains the azole antifungal itraconazole, is formulated using the Company’s proprietary SUBA (SUper-BioAvailable) technology which improves the bioavailability of poorly soluble drugs.